
Greenwich LifeSciences, Inc.: financial statements
Price
$19.25
November 20, 2026Market cap $283M
What Ploutos Investor adds for Greenwich LifeSciences
Part of Ploutos Investor, €9.99 a month
- The full history: 7 fiscal years, from 2019
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Notes on these figures
- The share price has risen 40% since Nov 16, 2026, when the 10-Q these figures come from was filed ($13.76 then, $19.25 on Nov 20, 2026). The figures date from before that move.10-Q
- The filings show substantial debt that is not stated in a form we can read. The debt, net cash, enterprise value, the multiples built on it and the return on invested capital would leave that debt out, so we leave them out.
Financial statements
Each fiscal year's income statement, balance sheet and cash flow as the company filed them, and the latest quarters.
Click a line to see it on the chart.
Operating income
| Line | 2023 | 2024 | 2025 | Average a year |
|---|---|---|---|---|
| Operating income | -$9.3M | -$18M | -$19M | |
| Net income | -$8.9M | -$17M | -$19M | |
| Earnings per share | -$0.69 | -$1.34 | -$1.43 | |
| Earnings per share, basic | -$0.69 | -$1.34 | -$1.43 |
Financial statements
GLSI's revenue, profits and cash flows from 2019 to 2022, 4 more fiscal years
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 5 fiscal years.
Amounts are in dollars as the company filed them in its annual reports (10-K or 20-F). Those reporting in another currency are converted at each fiscal year-end rate. Shares and earnings per share are adjusted for splits.
The metrics a company reports about itself (users, stores, subscribers) are read for S&P 500 companies only.
The full analysis
What do Greenwich LifeSciences's filings show?
These are Greenwich LifeSciences's figures from its filings. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
How much debt does GLSI have?
On December 31, 2025 Greenwich LifeSciences had total assets of $6.2M, debt of – and shareholders' equity of $353.2K.
Where are the figures from?
From Greenwich LifeSciences, Inc.'s annual and quarterly reports to the SEC, read from the structured data (XBRL) it files itself.
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.